Figure 5.

Percent of baseline (%) for lumbar spine bone mineral density (LSBMD) following NF-κB ligand inhibition with denosumab administered at (panels from left to right): 60 mg every 6 months (Q6M); 14 mg every Q6M for four doses and changed to 60 mg Q6M at month 24; 30 mg every 3 months for 8 doses and changed to 60 mg Q6M starting on month 36; 210 mg every 6 months for four doses then discontinued. Open circles present observed LSBMD and model-predicted values are represented by the solid line. A horizontal reference (dotted line) is included on each figure at the baseline value of 100%. Observed values were reproduced from Miller et al.¹⁴